2023
A New Solution to an Age-old Problem: A Review of Ketamine and Esketamine for Treatment-resistant Depression in Late Life
Balaram K, van Dyck L, Wilkins K, Maruca-Sullivan P. A New Solution to an Age-old Problem: A Review of Ketamine and Esketamine for Treatment-resistant Depression in Late Life. Current Geriatrics Reports 2023, 12: 93-102. DOI: 10.1007/s13670-023-00389-1.Peer-Reviewed Original ResearchTreatment-resistant major depressive disorderUse of ketamineOlder adultsKetamine/esketamineTreatment-resistant depressionAnti-depressant effectsEfficacy of ketamineLate-onset depressionOnset of actionCurrent treatment strategiesLate-life depressionCase series dataMajor depressive disorderTypes of patientsDegree of disabilityPotential long termOpen labelAntidepressant effectsOnset depressionOverall mortalityHealthcare utilizationTreatment algorithmCase reportCaregiver burdenClinical trials
2022
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review Of Psychiatry 2022, 30: 135-145. PMID: 35267254, DOI: 10.1097/hrp.0000000000000330.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSystematic reviewN-methyl-D-aspartate receptor antagonistAppropriate washout periodOpen-label trialPlacebo-controlled trialFirst-line treatmentRetrospective chart reviewUse of ketamineEffects of ketamineMeta-analysis protocolCombination of ketaminePubMed/MEDLINEPreferred Reporting ItemsMore effective treatmentsPotent N-methyl-d-aspartate receptor antagonistKetamine treatmentChart reviewGlutamate modulatorsGood tolerabilityReuptake inhibitorsWashout periodCase reportGlutamatergic neurotransmissionReceptor antagonist
2021
A systematic review of ketamine for the treatment of depression among older adults
Farheen S, Gupta A, Dhar R, Patadia P, Funaro M, Bhattacharya G, Tampi R. A systematic review of ketamine for the treatment of depression among older adults. American Journal Of Geriatric Psychiatry 2021, 29: s93-s96. DOI: 10.1016/j.jagp.2021.01.089.Peer-Reviewed Educational MaterialsPrimary outcome measureUse of ketamineLate-life depressionTreatment of depressionOlder adultsElectroconvulsive therapyReceptor antagonistLife depressionOutcome measuresCurrent evidenceDepressive symptomsOlder subjectsHamilton Depression Rating Scale scoresN-methyl-D-aspartate receptor antagonistSystematic reviewStudy participantsDepression Rating Scale scoresAdverse effectsBenefits of ketamineTolerability of ketamineCognitive adverse effectsCochrane Central RegisterTreatment-resistant depressionAnti-depressant effectsRelapse of symptoms
2020
A systematic review of ketamine for the treatment of depression among older adults
Gupta A, Dhar R, Patadia P, Funaro M, Bhattacharya G, Farheen SA, Tampi RR. A systematic review of ketamine for the treatment of depression among older adults. International Psychogeriatrics 2020, 33: 179-191. PMID: 32600480, DOI: 10.1017/s1041610220000903.Peer-Reviewed Educational MaterialsConceptsUse of ketaminePrimary outcome measureTreatment of depressionOlder adultsAdverse effectsOutcome measuresMontgomery-Asberg Depression Rating Scale scoreDepression Rating Scale scoresBenefits of ketamineCognitive adverse effectsRating Scale scoresEsketamine groupPlacebo groupRemission rateIntranasal ketamineKetamine administrationMADRS scoresInclusion criteriaDepressive symptomsCurrent evidenceScale scoreDepression symptomsKetamineSystematic reviewNegative trials
2018
S18. Hypotension after ketamine administration for refractory status epilepticus in patients at risk of shock
Sheikh Z, Owusu K, Ammar A, Landreneau M, Heck C, Gilmore E. S18. Hypotension after ketamine administration for refractory status epilepticus in patients at risk of shock. Clinical Neurophysiology 2018, 129: e149. DOI: 10.1016/j.clinph.2018.04.378.Peer-Reviewed Original ResearchRefractory status epilepticusStatus epilepticusEjection fractionApical hypokinesisShock indexMidazolam infusionDay 7Middle cerebral artery strokeAcute rehabilitation facilityDiscontinuation of ketamineDiscontinuation of vasopressorsElevated shock indexHospital day 7Improved ejection fractionInitiation of vasopressorsPotential hemodynamic effectsUse of vasopressorsChronic kidney diseaseAnti-seizure drugsUse of ketamineDoses of norepinephrineFocal clonic seizuresRisk of shockHemodynamic profileBeta blockers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply